國立高雄大學圖資館 |

Cardio-oncologymanagement of toxicities in the era of immunotherapy /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Cardio-oncologyedited by Antonio Russo ... [et al.].
Reminder of title:	management of toxicities in the era of immunotherapy /
other author:	Russo, Antonio.
Published:	Cham :Springer International Publishing :2022.
Description:	xiv, 122 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	CancerImmunotherapy
Online resource:	https://doi.org/10.1007/978-3-030-97744-3
ISBN:	9783030977443$q(electronic bk.)

Cardio-oncologymanagement of toxicities in the era of immunotherapy /
Cardio-oncologymanagement of toxicities in the era of immunotherapy /[electronic resource] :edited by Antonio Russo ... [et al.]. - Cham :Springer International Publishing :2022. - xiv, 122 p. :ill. (some col.), digital ;24 cm. - Current clinical pathology,2197-7828. - Current clinical pathology..

1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.

The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC) This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.

ISBN: 9783030977443$q(electronic bk.)

Standard No.: 10.1007/978-3-030-97744-3doiSubjects--Topical Terms:

933980
Cancer
--Immunotherapy

LC Class. No.: RC271.I45 / C37 2022

Dewey Class. No.: 616.994061

Cardio-oncologymanagement of toxicities in the era of immunotherapy /
LDR:03136nmm a2200325 a 4500 001 629285
003 DE-He213
005 20220809083351.0
007 cr nn 008maaau
008 230224s2022 sz s 0 eng d
020 $a 9783030977443$q(electronic bk.)
020 $a 9783030977436$q(paper)
024 7 $a 10.1007/978-3-030-97744-3 $2 doi
035 $a 978-3-030-97744-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45 $b C37 2022
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994061 $2 23
090 $a RC271.I45 $b C267 2022
245 0 0 $a Cardio-oncology $h [electronic resource] : $b management of toxicities in the era of immunotherapy / $c edited by Antonio Russo ... [et al.].
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2022.
300 $a xiv, 122 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Current clinical pathology, $x 2197-7828
505 0 $a 1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.
520 $a The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC) This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.
650 0 $a Cancer $x Immunotherapy $x Complications. $3 933980
650 0 $a Cardiovascular toxicology. $3 273674
650 1 4 $a Oncology. $3 195181
650 2 4 $a Cardiology. $3 273804
650 2 4 $a Pathology. $3 196513
650 2 4 $a Internal Medicine. $3 273839
700 1 $a Russo, Antonio. $3 558891
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Current clinical pathology. $3 558894
856 4 0 $u https://doi.org/10.1007/978-3-030-97744-3
950 $a Medicine (SpringerNature-11650)